Wanhuida Intellectual Property
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyTiejun Tang, Yuming Wang, and Jianhui Li of Wanhuida Intellectual Property discuss the evolving landscape in China around ‘offering for sale’, with reference to a high-profile Supreme People’s Court case involving a patented drug -
Sponsored by Wanhuida Intellectual PropertyXiaohui Wu of Wanhuida Intellectual Property reports on a ruling by the Supreme People’s Court of China that emphasises that the determination of common knowledge in the assessment of inventiveness should be incontrovertible
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
-
Sponsored by Wanhuida Intellectual PropertyJianhui Li and Honghui Hu of Wanhuida Intellectual Property discuss the antitrust scrutiny of China’s Supreme People’s Court in a patent infringement appeal concerning reverse payment settlement agreement
-
Sponsored by Wanhuida Intellectual PropertyFeng (Janet) Zheng of Wanhuida Intellectual Property provides an insight into obtaining evidence on the infringing product/process and the calculation of damages in China
-
Sponsored by Wanhuida Intellectual PropertyThe China Patent Office upheld the validity of the patent over the antihistamine desloratadine citrate disodium, as Yue Guan from Wanhuida Intellectual Property explains
